<DOC>
	<DOCNO>NCT00003960</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus donor bone marrow transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Donor Bone Marrow Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine 1-year survival rate patient hematologic malignancy treatment HLA-matched allogeneic bone marrow transplantation high-dose chemotherapy . OUTLINE : Patients receive oral busulfan four time day day -8 -5 , cyclophosphamide IV 1 hour day -4 -1 , methylprednisolone IV 1 hour every 12 hour day -2 0 . CD34+ stem cell augment donor bone marrow infuse day 0 . Methylprednisolone administer IV 1 hour day 5-16 , taper . Patients follow every 6 month 1 year annually thereafter . PROJECTED ACCRUAL : A total 36 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follow : Chronic myelogenous leukemia ( CML ) first chronic phase Myelodysplastic syndrome Refractory anemia excess blast ( RAEB ) RAEB transformation Secondary leukemia untreated complete remission 1 ( CR1 ) Acute myeloid leukemia complete remission 2 ( CR2 ) Acute lymphocytic leukemia ( ALL ) CR2 Highrisk acute leukemia CR1 Ph+ ALL CR1 consolidation induction chemotherapy Must qualify allogeneic bone marrow transplantation ( BMT ) No HLAmatched , sibling donor BMT available No current CNS disease No history 2 episode active CNS disease PATIENT CHARACTERISTICS : Age : 19 55 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : LVEF least 45 % No active congestive heart failure , arrhythmia , angina pectoris No myocardial infarction within past 12 month Pulmonary : FEV1 FVC least 50 % predict ( 75 % predict received prior thoracic mantle radiotherapy ) Other : No active serious infection ( e.g. , mucormycosis , uncontrolled aspergillosis , tuberculosis ) HIV negative Not pregnant Fertile patient must use effective contraception No concurrent debilitate medical psychiatric illness would preclude compliance No prior malignancy except curatively treat skin cancer carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior autologous allogeneic bone marrow transplantation No prior transfusion donor Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>